Intrapleural Amphotericin B for Aspergillus Empyema After Lung Transplantation
Introduction: Aspergillus empyema occurs rarely after lung transplantation and there is no standard approach to treatment. Adequate drug penetration to the pleural space has been described for systemic voriconazole and micafungin. Clinical and microbiologic cure was achieved in 3 cases of non-transplant patients with systemic voriconazole plus caspofungin and intrapleural amphotericin. Here we present a case of aspergillus empyema treated with intrapleural amphotericin B post lung transplant. (Source: The Journal of Heart and Lung Transplantation)
Source: The Journal of Heart and Lung Transplantation - April 1, 2024 Category: Transplant Surgery Authors: A. Driver, , R. Wright, N. Partovi, J. Choi, J. Costa, R. Levy, R. Nador, C. Bergeron, A. Kapasi, J. Samuels, J. Wilson, J. Yee Source Type: research
Antifungal effects of echinocandins diminish when exposed to intestinal lumen contents: a finding with potentially significant clinical implications
In this study, caspofungin and micafungin, the two most commonly used echinocandins, were evaluated in various in vitro environments simulating intestinal lumen. The results revealed that while both antifungals are effective in standard medium, their efficacy significantly diminishes in the presence of human small bowel aspirates and bovine bile. The study suggests that bowel contents and specifically bile acids may be a suppressive component, hindering the antifungal effects of echinocandins. This novel exploration sheds light on the poor oral bioavailability of echinocandins. The findings imply that echinocandins alone, ...
Source: Frontiers in Pharmacology - March 27, 2024 Category: Drugs & Pharmacology Source Type: research
Outcomes by < em > Candida < /em > spp. in the ReSTORE Phase 3 trial of rezafungin versus caspofungin for candidemia and/or invasive candidiasis
Antimicrob Agents Chemother. 2024 Mar 25:e0158423. doi: 10.1128/aac.01584-23. Online ahead of print.ABSTRACTRezafungin is a long-acting, intravenously administered echinocandin for the treatment of candidemia and invasive candidiasis (IC). Non-inferiority of rezafungin vs caspofungin for the treatment of adults with candidemia and/or IC was demonstrated in the Phase 3 ReSTORE study based on the primary endpoints of day 14 global cure and 30-day all-cause mortality. Here, an analysis of ReSTORE data evaluating efficacy outcomes by baseline Candida species is described. Susceptibility testing was performed for Candida specie...
Source: Antimicrobial Agents and Chemotherapy - March 25, 2024 Category: Microbiology Authors: Jeffrey B Locke Chris M Pillar Mariana Castanheira Cecilia G Carvalhaes David Andes Jalal A Aram Christina Andrzejewski Ken Bartizal Anita F Das Taylor Sandison George R Thompson Peter G Pappas Source Type: research
Outcomes by < em > Candida < /em > spp. in the ReSTORE Phase 3 trial of rezafungin versus caspofungin for candidemia and/or invasive candidiasis
Antimicrob Agents Chemother. 2024 Mar 25:e0158423. doi: 10.1128/aac.01584-23. Online ahead of print.ABSTRACTRezafungin is a long-acting, intravenously administered echinocandin for the treatment of candidemia and invasive candidiasis (IC). Non-inferiority of rezafungin vs caspofungin for the treatment of adults with candidemia and/or IC was demonstrated in the Phase 3 ReSTORE study based on the primary endpoints of day 14 global cure and 30-day all-cause mortality. Here, an analysis of ReSTORE data evaluating efficacy outcomes by baseline Candida species is described. Susceptibility testing was performed for Candida specie...
Source: Antimicrobial Agents and Chemotherapy - March 25, 2024 Category: Microbiology Authors: Jeffrey B Locke Chris M Pillar Mariana Castanheira Cecilia G Carvalhaes David Andes Jalal A Aram Christina Andrzejewski Ken Bartizal Anita F Das Taylor Sandison George R Thompson Peter G Pappas Source Type: research
Outcomes by < em > Candida < /em > spp. in the ReSTORE Phase 3 trial of rezafungin versus caspofungin for candidemia and/or invasive candidiasis
Antimicrob Agents Chemother. 2024 Mar 25:e0158423. doi: 10.1128/aac.01584-23. Online ahead of print.ABSTRACTRezafungin is a long-acting, intravenously administered echinocandin for the treatment of candidemia and invasive candidiasis (IC). Non-inferiority of rezafungin vs caspofungin for the treatment of adults with candidemia and/or IC was demonstrated in the Phase 3 ReSTORE study based on the primary endpoints of day 14 global cure and 30-day all-cause mortality. Here, an analysis of ReSTORE data evaluating efficacy outcomes by baseline Candida species is described. Susceptibility testing was performed for Candida specie...
Source: Antimicrobial Agents and Chemotherapy - March 25, 2024 Category: Microbiology Authors: Jeffrey B Locke Chris M Pillar Mariana Castanheira Cecilia G Carvalhaes David Andes Jalal A Aram Christina Andrzejewski Ken Bartizal Anita F Das Taylor Sandison George R Thompson Peter G Pappas Source Type: research
Rise and fall of Caspofungin: the current status of Caspofungin as a treatment for Cryptococcus neoformans infection
Future Microbiology, Ahead of Print. (Source: Future Microbiology)
Source: Future Microbiology - March 18, 2024 Category: Microbiology Authors: Tawanny KB Aguiar Ana CM Costa Nilton AS Neto Daiane MS Brito Cleverson DT Freitas Jo ão MM Neto Felipe P Mesquita Pedro FN Souza Source Type: research
Modeling of intravenous caspofungin administration using an intestine-on-chip reveals altered Candida albicans microcolonies and pathogenicity
Biomaterials. 2024 Mar 9;307:122525. doi: 10.1016/j.biomaterials.2024.122525. Online ahead of print.ABSTRACTCandida albicans is a commensal yeast of the human intestinal microbiota that, under predisposing conditions, can become pathogenic and cause life-threatening systemic infections (candidiasis). Fungal-host interactions during candidiasis are commonly studied using conventional 2D in vitro models, which have provided critical insights into the pathogenicity. However, microphysiological models with a higher biological complexity may be more suitable to mimic in vivo-like infection processes and antifungal drug efficacy...
Source: Biomaterials - March 15, 2024 Category: Materials Science Authors: Tim Kaden Raquel Alonso-Roman Parastoo Akbarimoghaddam Alexander S Mosig Katja Graf Martin Raasch Bianca Hoffmann Marc T Figge Bernhard Hube Mark S Gresnigt Source Type: research
Pulmonary surfactant impacts in vitro activity of selected antifungal drugs against Candida krusei and Candida albicans
ConclusionThis in-vitro study highlights the concentration-dependent inhibitory effect of surfactant on antifungal activity againstC. krusei and, to some extent,C. albicans, necessitating further clinical validation for invasive lung mycoses treatment. (Source: European Journal of Clinical Microbiology and Infectious Diseases)
Source: European Journal of Clinical Microbiology and Infectious Diseases - March 14, 2024 Category: Microbiology Source Type: research
Novel automated antifungal susceptibility testing system for yeasts based on dual-detection algorithm of turbidimetry and colorimetry
Conclusion. Given the above, it can be argued that the utilization of Fungus AST is a discretionary automated approach. More improvements are needed in Fungus AST compared to the BMD system for a wider range of clinical isolates, including different types of fungi.PMID:38440953 | DOI:10.1099/jmm.0.001811 (Source: Journal of Medical Microbiology)
Source: Journal of Medical Microbiology - March 5, 2024 Category: Microbiology Authors: Tingting Shen Piao Liu Dongmiao Chen Duoduo Liu Juan Fang Qian Wang Yinjuan Xu Chunjuan Tan Congrong Wang Source Type: research
Novel automated antifungal susceptibility testing system for yeasts based on dual-detection algorithm of turbidimetry and colorimetry
Conclusion. Given the above, it can be argued that the utilization of Fungus AST is a discretionary automated approach. More improvements are needed in Fungus AST compared to the BMD system for a wider range of clinical isolates, including different types of fungi.PMID:38440953 | DOI:10.1099/jmm.0.001811 (Source: Journal of Medical Microbiology)
Source: Journal of Medical Microbiology - March 5, 2024 Category: Microbiology Authors: Tingting Shen Piao Liu Dongmiao Chen Duoduo Liu Juan Fang Qian Wang Yinjuan Xu Chunjuan Tan Congrong Wang Source Type: research
Novel automated antifungal susceptibility testing system for yeasts based on dual-detection algorithm of turbidimetry and colorimetry
Conclusion. Given the above, it can be argued that the utilization of Fungus AST is a discretionary automated approach. More improvements are needed in Fungus AST compared to the BMD system for a wider range of clinical isolates, including different types of fungi.PMID:38440953 | DOI:10.1099/jmm.0.001811 (Source: Journal of Medical Microbiology)
Source: Journal of Medical Microbiology - March 5, 2024 Category: Microbiology Authors: Tingting Shen Piao Liu Dongmiao Chen Duoduo Liu Juan Fang Qian Wang Yinjuan Xu Chunjuan Tan Congrong Wang Source Type: research
Novel automated antifungal susceptibility testing system for yeasts based on dual-detection algorithm of turbidimetry and colorimetry
Conclusion. Given the above, it can be argued that the utilization of Fungus AST is a discretionary automated approach. More improvements are needed in Fungus AST compared to the BMD system for a wider range of clinical isolates, including different types of fungi.PMID:38440953 | DOI:10.1099/jmm.0.001811 (Source: Journal of Medical Microbiology)
Source: Journal of Medical Microbiology - March 5, 2024 Category: Microbiology Authors: Tingting Shen Piao Liu Dongmiao Chen Duoduo Liu Juan Fang Qian Wang Yinjuan Xu Chunjuan Tan Congrong Wang Source Type: research
